A Research Agenda for Malaria Eradication: Vaccines
暂无分享,去创建一个
Prashant Yadav | Rhoel R. Dinglasan | Robert W. Sauerwein | Ashley J. Birkett | Myron M. Levine | Stephen L. Hoffman | Dyann F. Wirth | B. F. Hall | Gina Brown | Pedro L. Alonso | Patrick E. Duffy | Quique Bassat | S. Hoffman | R. Sinden | Q. Bassat | A. Cowman | D. Wirth | M. Levine | K. Mendis | F. Binka | P. Alonso | S. Abdulla | B. Greenwood | C. Loucq | R. Dinglasan | C. Chitnis | C. Guinovart | R. Sauerwein | C. Plowe | S. Herrera | M. Arévalo-Herrera | A. Saul | Prashant Yadav | H. Portillo | P. Duffy | O. Leroy | V. Moorthy | Louis Schofield | G. Corradin | A. Birkett | L. Schofield | Brian Greenwood | Fred Binka | Christopher V. Plowe | J. Stubbs | O. Puijalon | Alan F. Cowman | D. Gargallo | Caterina Guinovart | Odile Puijalon | Jessica Milman | Salim Abdulla | Kamini N. Mendis | Chetan E. Chitnis | J. Milman | T. Villafana | Sócrates Herrera | Myriam Arévalo-Herrera | Gina Brown | Terrell Carter | C. Loucq | P. Agre | G. Corradin | J. Culpepper | H. del Portillo | D. Gargallo | A. Lanzavecchia | O. Leroy | V. S. Moorthy | G. Pleuschke | Susan D. Reed | A. Saul | R. R. Sinden | J. Stubbs | T. Villafana | R. Ballou | W. Brandt | A. Brooks | A. Golden | C. Lee | J. Nunes | T. Raphael | H. Richards | C. Warren | C. Woods | P. Agre | C. Woods | A. Lanzavecchia | S. Reed | A. Golden | J. Culpepper | J. Nunes | Terrell C. Carter | T. Raphael | G. Pleuschke | R. Ballou | W. Brandt | A. Brooks | C. Lee | H. Richards | C. Warren | Gina M. Brown | S. D. Reed
[1] A. Holder,et al. Function of Region I and II Adhesive Motifs ofPlasmodium falciparum Circumsporozoite Protein in Sporozoite Motility and Infectivity* , 2002, The Journal of Biological Chemistry.
[2] Kim-Sung Lee,et al. Plasmodium knowlesi from archival blood films: Further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo , 2009, International journal for parasitology.
[3] M. Khatri,et al. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. , 2009, The American journal of tropical medicine and hygiene.
[4] Yongyuth Yuthavong,et al. A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.
[5] R. Adegbola,et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study , 2005, The Lancet.
[6] Anil K Ghosh,et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen , 2007, Proceedings of the National Academy of Sciences.
[7] R. Snow,et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya , 2008, The Lancet.
[8] Nicolas Maire,et al. What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines , 2008, PloS one.
[9] C. Plowe,et al. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’ , 2009, Parasite immunology.
[10] Nicholas J White,et al. Vivax malaria: neglected and not benign. , 2007, The American journal of tropical medicine and hygiene.
[11] E. Angov,et al. A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli , 2009, PloS one.
[12] Q. Bassat,et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial , 2005, The Lancet.
[13] Petra Schneider,et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. , 2006, The Journal of infectious diseases.
[14] M. Levine,et al. The Role of Research in Viral Disease Eradication and Elimination Programs: Lessons for Malaria Eradication , 2011, PLoS medicine.
[15] M. Dixon,et al. Sex in Plasmodium: a sign of commitment. , 2008, Trends in parasitology.
[16] S. Hoffman,et al. Antibodies against the Plasmodium falciparum Receptor Binding Domain of EBA-175 Block Invasion Pathways That Do Not Involve Sialic Acids , 2000, Infection and Immunity.
[17] Priyabrata Pattnaik,et al. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. , 2002, Molecular and biochemical parasitology.
[18] David Schellenberg,et al. A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.
[19] D. Henderson. Principles and lessons from the smallpox eradication programme. , 1987, Bulletin of the World Health Organization.
[20] J. John. Role of injectable and oral polio vaccines in polio eradication , 2009, Expert review of vaccines.
[21] M. Fay,et al. Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.
[22] Zbynek Bozdech,et al. Antibodies Targeting the PfRH1 Binding Domain Inhibit Invasion of Plasmodium falciparum Merozoites , 2008, PLoS pathogens.
[23] Surveillance.. A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance , 2011, PLoS medicine.
[24] J. Acharya,et al. Thrombocytopenia in Plasmodium falciparum, Plasmodium vivax and mixed infection malaria: A study from Bikaner (Northwestern India) , 2010, Platelets.
[25] D. Conway,et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis , 2008, The Lancet.
[26] Frank H. Collins,et al. A Research Agenda for Malaria Eradication: Vector Control , 2011, PLoS medicine.
[27] J Mouchet,et al. DDT house spraying and re-emerging malaria , 2000, The Lancet.
[28] A Research Agenda for Malaria Eradication: Cross-Cutting Issues for Eradication , 2011, PLoS medicine.
[29] Sumana Chakravarty,et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria , 2010, Human vaccines.
[30] C. Chitnis,et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. , 1994, Science.
[31] S. D. de Vlas,et al. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data , 2005, Parasitology.
[32] K. Mendis,et al. The neglected burden of Plasmodium vivax malaria. , 2001, The American journal of tropical medicine and hygiene.
[33] V. Nussenzweig,et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of plasmodium falciparum sporozoites , 1992, Cell.
[34] C. Chitnis,et al. Plasmodium vivax Invasion of Human Erythrocytes Inhibited by Antibodies Directed against the Duffy Binding Protein , 2007, PLoS medicine.
[35] Priyabrata Pattnaik,et al. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. , 2007, Vaccine.
[36] Inacio Mandomando,et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.
[37] A. Crisanti,et al. The A‐domain and the thrombospondin‐related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands , 1999, The EMBO journal.
[38] R. Carter. Transmission blocking malaria vaccines. , 2001, Vaccine.
[39] M. Mota,et al. Migration through host cells activates Plasmodium sporozoites for infection , 2003, Nature Medicine.
[40] A. Holder,et al. Effective induction of high-titer antibodies by viral vector vaccines , 2008, Nature Medicine.
[41] Thomas Smith,et al. A Research Agenda for Malaria Eradication: Modeling , 2011, PLoS medicine.
[42] Manuel Llinás,et al. A Research Agenda for Malaria Eradication: Basic Science and Enabling Technologies , 2011, PLoS medicine.
[43] R. Price,et al. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance , 2009, Current opinion in infectious diseases.
[44] W. Moss,et al. Global measles elimination , 2006, Nature Reviews Microbiology.
[45] H. Stunnenberg,et al. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice , 2008, Proceedings of the National Academy of Sciences.
[46] A. Das,et al. Plasmodium vivax Malaria , 2005, Emerging infectious diseases.
[47] D. Conway,et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] J. Sattabongkot,et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. , 2005, Vaccine.
[49] Andrea Crisanti,et al. TRAP Is Necessary for Gliding Motility and Infectivity of Plasmodium Sporozoites , 1997, Cell.